These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 32661327)

  • 1. Comparisons of screening strategies for identifying Lynch syndrome among patients with MLH1-deficient colorectal cancer.
    Xiao B; Luo J; Xie E; Kong L; Tang J; Liu D; Mao L; Sui Q; Li W; Hong Z; Pan Z; Jiang W; Ding PR
    Eur J Hum Genet; 2020 Nov; 28(11):1555-1562. PubMed ID: 32661327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selection of patients with germline MLH1 mutated Lynch syndrome by determination of MLH1 methylation and BRAF mutation.
    Bouzourene H; Hutter P; Losi L; Martin P; Benhattar J
    Fam Cancer; 2010 Jun; 9(2):167-72. PubMed ID: 19949877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient molecular screening of Lynch syndrome by specific 3' promoter methylation of the MLH1 or BRAF mutation in colorectal cancer with high-frequency microsatellite instability.
    Nakagawa H; Nagasaka T; Cullings HM; Notohara K; Hoshijima N; Young J; Lynch HT; Tanaka N; Matsubara N
    Oncol Rep; 2009 Jun; 21(6):1577-83. PubMed ID: 19424639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumour MLH1 promoter region methylation testing is an effective prescreen for Lynch Syndrome (HNPCC).
    Newton K; Jorgensen NM; Wallace AJ; Buchanan DD; Lalloo F; McMahon RF; Hill J; Evans DG
    J Med Genet; 2014 Dec; 51(12):789-96. PubMed ID: 25280751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A tailored approach to BRAF and MLH1 methylation testing in a universal screening program for Lynch syndrome.
    Adar T; Rodgers LH; Shannon KM; Yoshida M; Ma T; Mattia A; Lauwers GY; Iafrate AJ; Chung DC
    Mod Pathol; 2017 Mar; 30(3):440-447. PubMed ID: 28059100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of somatic mutl homolog 1 promoter hypermethylation in Lynch syndrome colorectal cancer.
    Moreira L; Muñoz J; Cuatrecasas M; Quintanilla I; Leoz ML; Carballal S; Ocaña T; López-Cerón M; Pellise M; Castellví-Bel S; Jover R; Andreu M; Carracedo A; Xicola RM; Llor X; Boland CR; Goel A; Castells A; Balaguer F;
    Cancer; 2015 May; 121(9):1395-404. PubMed ID: 25557234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective, multicenter, population-based study of BRAF mutational analysis for Lynch syndrome screening.
    Bessa X; Ballesté B; Andreu M; Castells A; Bellosillo B; Balaguer F; Castellví-Bel S; Paya A; Jover R; Alenda C; Titó L; Martinez-Villacampa M; Vilella A; Xicola RM; Pons E; Llor X;
    Clin Gastroenterol Hepatol; 2008 Feb; 6(2):206-14. PubMed ID: 18096441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MLH1 promoter hypermethylation in the analytical algorithm of Lynch syndrome: a cost-effectiveness study.
    Gausachs M; Mur P; Corral J; Pineda M; González S; Benito L; Menéndez M; Espinàs JA; Brunet J; Iniesta MD; Gruber SB; Lázaro C; Blanco I; Capellá G
    Eur J Hum Genet; 2012 Jul; 20(7):762-8. PubMed ID: 22274583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of predictive models in daily practice for the identification of patients with Lynch syndrome.
    Tresallet C; Brouquet A; Julié C; Beauchet A; Vallot C; Ménégaux F; Mitry E; Radvanyi F; Malafosse R; Rougier P; Nordlinger B; Laurent-Puig P; Boileau C; Emile JF; Muti C; Penna C; Hofmann-Radvanyi H
    Int J Cancer; 2012 Mar; 130(6):1367-77. PubMed ID: 21520036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer.
    Hampel H; Pearlman R; Beightol M; Zhao W; Jones D; Frankel WL; Goodfellow PJ; Yilmaz A; Miller K; Bacher J; Jacobson A; Paskett E; Shields PG; Goldberg RM; de la Chapelle A; Shirts BH; Pritchard CC;
    JAMA Oncol; 2018 Jun; 4(6):806-813. PubMed ID: 29596542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lynch syndrome screening in colorectal cancer: results of a prospective 2-year regional programme validating the NICE diagnostics guidance pathway throughout a 5.2-million population.
    West NP; Gallop N; Kaye D; Glover A; Young C; Hutchins GGA; Brockmoeller SF; Westwood AC; Rossington H; Quirke P;
    Histopathology; 2021 Nov; 79(5):690-699. PubMed ID: 33872400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MLH1-deficient Colorectal Carcinoma With Wild-type BRAF and MLH1 Promoter Hypermethylation Harbor KRAS Mutations and Arise From Conventional Adenomas.
    Farchoukh L; Kuan SF; Dudley B; Brand R; Nikiforova M; Pai RK
    Am J Surg Pathol; 2016 Oct; 40(10):1390-9. PubMed ID: 27438990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methylation analysis of MLH1 improves the selection of patients for genetic testing in Lynch syndrome.
    Pérez-Carbonell L; Alenda C; Payá A; Castillejo A; Barberá VM; Guillén C; Rojas E; Acame N; Gutiérrez-Aviñó FJ; Castells A; Llor X; Andreu M; Soto JL; Jover R
    J Mol Diagn; 2010 Jul; 12(4):498-504. PubMed ID: 20489114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amplicon-based NGS test for assessing MLH1 promoter methylation and its correlation with BRAF mutation in colorectal cancer patients.
    da Silva SIO; Domingos TA; Kupper BEC; De Brot L; Aguiar Junior S; Carraro DM; Torrezan GT
    Exp Mol Pathol; 2023 Apr; 130():104855. PubMed ID: 36736685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Costs and outcomes of Lynch syndrome screening in the Australian colorectal cancer population.
    Cenin DR; Naber SK; Lansdorp-Vogelaar I; Jenkins MA; Buchanan DD; Preen DB; Ee HC; O'Leary P
    J Gastroenterol Hepatol; 2018 Oct; 33(10):1737-1744. PubMed ID: 29645364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Finding the needle in a haystack: identification of cases of Lynch syndrome with MLH1 epimutation.
    Hitchins MP
    Fam Cancer; 2016 Jul; 15(3):413-22. PubMed ID: 26886015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of MLH1 constitutional methylation for Lynch syndrome diagnosis in patients with tumor MLH1 downregulation.
    Pinto D; Pinto C; Guerra J; Pinheiro M; Santos R; Vedeld HM; Yohannes Z; Peixoto A; Santos C; Pinto P; Lopes P; Lothe R; Lind GE; Henrique R; Teixeira MR
    Cancer Med; 2018 Feb; 7(2):433-444. PubMed ID: 29341452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is tumor testing efficiency for Lynch syndrome different in rectal and colon cancer?
    Marabelli M; Gandini S; Rafaniello PR; Calvello M; Tolva G; Feroce I; Lazzeroni M; Marino E; Dal Molin M; Trovato C; Guerrieri-Gonzaga A; Petz WL; Barberis M; Bertario L; Bonanni B
    Dig Liver Dis; 2020 Dec; 52(12):1503-1511. PubMed ID: 32620519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAF mutation in sporadic colorectal cancer and Lynch syndrome.
    Thiel A; Heinonen M; Kantonen J; Gylling A; Lahtinen L; Korhonen M; Kytölä S; Mecklin JP; Orpana A; Peltomäki P; Ristimäki A
    Virchows Arch; 2013 Nov; 463(5):613-21. PubMed ID: 23963522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct clinical phenotype and genetic testing strategy for Lynch syndrome in China based on a large colorectal cancer cohort.
    Dong L; Jin X; Wang W; Ye Q; Li W; Shi S; Guo L; Ying J; Zou S
    Int J Cancer; 2020 Jun; 146(11):3077-3086. PubMed ID: 32030746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.